Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis

Yosuke Kasai^{1

2}, Eric K Nakakura³, Akitada Yogo^{4

3}, Kazuyuki Nagai⁴, Toshihiko Masui^{4

5}, Etsuro Hatano⁴

Affiliations

¹ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. yokasai@kuhp.kyoto-u.ac.jp.
² Department of Surgery, University of California San Francisco, San Francisco, CA, USA. yokasai@kuhp.kyoto-u.ac.jp.
³ Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
⁴ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁵ Department of Surgery, Kurashiki Central Hospital, Okayama, Japan.

Comment

Yosuke Kasai et al. Ann Surg Oncol. 2023 Sep.

. 2023 Sep;30(9):5457-5458.

doi: 10.1245/s10434-023-13834-4. Epub 2023 Jul 2.

Yosuke Kasai^{1

2}, Eric K Nakakura³, Akitada Yogo^{4

3}, Kazuyuki Nagai⁴, Toshihiko Masui^{4

5}, Etsuro Hatano⁴

¹ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. yokasai@kuhp.kyoto-u.ac.jp.
² Department of Surgery, University of California San Francisco, San Francisco, CA, USA. yokasai@kuhp.kyoto-u.ac.jp.
³ Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
⁴ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁵ Department of Surgery, Kurashiki Central Hospital, Okayama, Japan.

No abstract available

Comment in

Reply to "Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis".
Gudmundsdottir H, Cleary SP, Halfdanarson TR. Gudmundsdottir H, et al. Ann Surg Oncol. 2023 Sep;30(9):5459-5460. doi: 10.1245/s10434-023-13839-z. Epub 2023 Jul 2. Ann Surg Oncol. 2023. PMID: 37394671 No abstract available.

Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.
Gudmundsdottir H, Habermann EB, Vierkant RA, Starlinger P, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Halfdanarson TR, Nagorney DM, Cleary SP. Gudmundsdottir H, et al. Ann Surg Oncol. 2023 Aug;30(8):4840-4851. doi: 10.1245/s10434-023-13372-z. Epub 2023 May 19. Ann Surg Oncol. 2023. PMID: 37208566 Free PMC article.

1. Gudmundsdottir H, Habermann EB, Vierkant RA, et al. Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term follow-up evaluation of more than 500 patients. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13372-z . - DOI - PubMed - PMC
1. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37. - DOI - PubMed
1. Graff-Baker AN, Sauer DA, Pommier SJ, et al. Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients. Surgery. 2014;156(6):1369–76 (discussion 1376–7). - DOI - PubMed
1. Maxwell JE, Sherman SK, O’Dorisio TM, et al. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery. 2016;159(1):320–33. - DOI - PubMed
1. Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218–25. - DOI - PubMed